Post-translational modifications (PTMs) are crucial mechanisms that underlie the intricacies
of biological systems and disease mechanisms. This review focuses on the latest …

Traditional targets and modalities that have provided rich substrates for medicine design
and decades of productive industrial and academic research are not the primary drug …

A generalized therapeutic strategy for various disease conditions, including cancer, is to
deplete or inactivate harmful protein targets. Various forms of protein or gene silencing …

Selective protein degradation maintains cellular homeostasis, but this process is disrupted
in many diseases. Targeted protein degradation (TPD) approaches, built upon existing …

Simple Summary Beta-transducin repeat-containing proteins (β-TrCPs) are a component of
the E3 ubiquitin ligase complex and function in many cellular processes to maintain protein …

Versatile tag‐based strategies have been developed to control the stability of target proteins.
These approaches are highly useful for validation of unliganded drug targets and for …

Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor
survival and heightened response to immune checkpoint inhibitors (ICIs). Two major barriers …

Small‐molecule‐induced protein degradation has emerged as a compelling approach for
targeted elimination of proteins from cells or extracellular space by directing these proteins …

Targeted protein therapeutics have garnered significant interest in modern drug discovery,
in part due to their ability to target classically “undruggable” proteins.“Undruggable” proteins …

KGaA, GSK and Eisai with activities in the development and distribution of ivermectin,
praziquantel, albendazole and diethylcarbamazine, to name just a few. Third, on top of a …